On November 11, Veracyte rose 6.48% in Regular Trading, trading at $25.5 per share, with turnover of $6.8761 million.
The move followed analyst commentary that kept a constructive stance on the stock, including a maintained Overweight rating and continued Buy recommendations even after recent target-price cuts, supporting a rebound after the sharp post-earnings selloff.
Background context shows Veracyte reported third-quarter revenue of $151.8 million and adjusted EPS of $0.51, both above market expectations. However, the company narrowed full-year revenue guidance to $590 million to $593 million and lowered its testing-revenue outlook, which had triggered a steep decline earlier in the week. More recently, one firm downgraded the stock to Market Perform with a $35 target, while other firms reduced targets but kept positive ratings, indicating that the latest rise appears more consistent with sentiment repair than a change in operating fundamentals.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments